Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment / Viral Associated Cancers and Disorders · Journal article
Frontiers in Oncology · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a case report of one HIV-positive patient with high-volume mHSPC who received rezvilutamide plus ADT while on efavirenz-based antiretroviral therapy and achieved marked PSA decline and clinical improvement. The anecdotal nature of the report, absence of a control arm, and single-patient data mean it can only raise the hypothesis that this drug combination may be feasible and tolerable in this specific context; it does not establish efficacy or safety in any population.
Case report. One HIV-positive patient with high-volume metastatic hormone-sensitive prostate cancer receiving efavirenz-based antiretroviral therapy.. Intervention: Rezvilutamide combined with androgen deprivation therapy (ADT). n = 1.
PSA declined from 21,788.320 ng/mL to 4.315 ng/mL in a single patient Significant clinical improvement and sustained HIV viral suppression reported Favorable short-term tolerability profile observed
Drug-drug interaction effects and tolerability described anecdotally without quantitative safety monitoring details. Favorable short-term tolerability profile observed
This single case does not provide evidence sufficient to guide treatment decisions. It illustrates a potential feasibility scenario and may warrant prospective investigation in a controlled trial, but cannot be used to support or refute the use of rezvilutamide in mHSPC or in patients with HIV co-infection.
A single case report with no comparator, describing anecdotal response to a novel drug combination in an unusual population; insufficient to change practice or confirm efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This single case does not provide evidence sufficient to guide treatment decisions. It illustrates a potential feasibility scenario and may warrant prospective investigation in a controlled trial, but cannot be used to support or refute the use of rezvilutamide in mHSPC or in patients with HIV co-infection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This case report describes a patient with metastatic hormone-sensitive prostate cancer (mHSPC), high tumor burden, and concurrent HIV infection receiving continuous efavirenz (a potent CYP3A4 inducer), who was treated with an intensified regimen based on androgen deprivation therapy (ADT) combined with the novel androgen receptor inhibitor rezvilutamide. Under rigorous multidisciplinary monitoring, this regimen achieved a rapid and profound response, characterized by a decline in prostate-specific antigen (PSA) levels from 21,788.320 ng/mL to 4.315 ng/mL, significant clinical improvement, sustained HIV viral suppression, and a favorable short-term tolerability profile. This case directly addresses the controversies and challenges regarding the use of intensified therapy in patients with comorbidities in current clinical practice, suggesting that key drug-drug interaction barriers may be manageable through personalized strategies and proactive management. This case provides a practical reference for implementing guideline-recommended treatment intensification principles in similar complex clinical scenarios, offering clinically relevant insights.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.